Skip to content
2000
Volume 23, Issue 10
  • ISSN: 1570-159X
  • E-ISSN: 1875-6190

Abstract

Background

The risk of developing progressive multifocal leukoencephalopathy (PML), a rare but potentially fatal opportunistic infection of the central nervous system caused by the J.C. virus (JCV), remains a primary concern associated with natalizumab therapy in the clinical management of patients diagnosed with multiple sclerosis (MS).

Materials and Methods

This study compared two tests, STRATIFY JCV™ DxSelect™, and IMMUNOWELL™ JCV antibody tests, for assessing the risk of PML in patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who had received disease-modifying therapy (DMT) with branded natalizumab (Tysabri®). The main objective was to determine the comparability of these tests in classifying PML risk. Eligible patients were selected from a database, and all specimens for the STRATIFY JCV™ DxSelect™ and IMMUNOWELL™ JCV antibody tests were collected on the same day. Patients were classified into three risk categories (low, intermediate, or high) based on threshold values for each test.

Results

The analysis showed 85.5% agreement between the two tests for risk classification. Ten discordant cases were identified, mainly between intermediate- and high-risk categories. Compared to STRATIFY JCV™ DxSelect™, IMMUNOWELL™ JCV antibody test tended to categorize more patients as higher risk. No significant association was found between discordance and prior use of immunosuppressant drugs and >24 doses of natalizumab. The agreement between tests, assessed with the weighted Cohen’s Kappa coefficient, was substantial (κ=0.6222).

Conclusions

Compared to the STRATIFY JCV™ DxSelect™, the IMMUNOWELL™ JCV test tends to place more patients in higher risk categories. Further, longitudinal studies are needed to evaluate the clinical impact of these differences in PML risk assessment.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cn/10.2174/011570159X372688250226110925
2025-04-07
2025-09-11

  • From This Site

    /content/journals/cn/10.2174/011570159X372688250226110925
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. HemmerB. WiendlH. RothK. WesselsH. HöflerJ. HornussC. LiedertB. SelmajK. Efficacy and safety of proposed biosimilar Natalizumab (PB006) in patients with relapsing-remitting multiple sclerosis.JAMA Neurol.202380329830710.1001/jamaneurol.2022.5007 36689214
     [Google Scholar]
  2. SelmajK. RothK. HöflerJ. VitzithumK. DerlaczR. von RichterO. HornussC. PoetzlJ. SingerB. JacobsL. Introducing the biosimilar paradigm to neurology: The totality of evidence for the first biosimilar Natalizumab.BioDrugs202438675576710.1007/s40259‑024‑00671‑4 39343860
     [Google Scholar]
  3. D’AmicoE. ZanghìA. LeoneC. TumaniH. PattiF. Treatment-related progressive multifocal leukoencephalopathy in multiple sclerosis: A comprehensive review of current evidence and future needs.Drug Saf.201639121163117410.1007/s40264‑016‑0461‑6 27696299
     [Google Scholar]
  4. BrewB.J. DaviesN.W.S. CinqueP. CliffordD.B. NathA. Progressive multifocal leukoencephalopathy and other forms of JC virus disease.Nat. Rev. Neurol.201061266767910.1038/nrneurol.2010.164 21131916
     [Google Scholar]
  5. ZanghìA. GalloA. AvolioC. CapuanoR. LucchiniM. PetraccaM. BonavitaS. LanzilloR. FerraroD. CurtiE. BuccafuscaM. CallariG. BaroneS. PontilloG. AbbadessaG. Di FrancescantonioV. SignorielloE. LusG. SolaP. GranellaF. ValentinoP. MirabellaM. PattiF. D’AmicoE. Exit strategies in Natalizumab-Treated RRMS at high risk of progressive multifocal leukoencephalopathy: A multicentre comparison study.Neurotherapeutics20211821166117410.1007/s13311‑021‑01037‑2 33844155
     [Google Scholar]
  6. TobosoI. Tejeda-VelardeA. Alvarez-LafuenteR. ArroyoR. HegenH. DeisenhammerF. Sainz de la MazaS. Alvarez-CermeñoJ.C. IzquierdoG. ParamoD. OlivaP. CasanovaB. Agüera-MoralesE. FranciottaD. GastaldiM. FernándezO. UrbanejaP. Garcia-DominguezJ.M. RomeroF. LaroniA. UccelliA. Perez-SempereA. SaizA. BlancoY. GalimbertiD. ScarpiniE. EspejoC. MontalbanX. RascheL. PaulF. GonzálezI. ÁlvarezE. RamoC. CamineroA.B. AladroY. CallesC. EguíaP. Belenguer-BenavidesA. Ramió-TorrentàL. QuintanaE. Martínez-RodríguezJ.E. OterinoA. López de SilanesC. CasanovaL.I. LandeteL. FrederiksenJ. BstehG. MuleroP. ComabellaM. HernándezM.A. EspiñoM. PrietoJ.M. PérezD. OtanoM. PadillaF. García-MerinoJ.A. NavarroL. MurielA. FrossardL.C. VillarL.M. New algorithms improving PML risk stratification in MS patients treated with Natalizumab.Front. Neurol.20201157943810.3389/fneur.2020.579438 33408681
     [Google Scholar]
  7. McGuiganC. CranerM. GuadagnoJ. KapoorR. MazibradaG. MolyneuxP. NicholasR. PalaceJ. PearsonO.R. RogD. YoungC.A. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: Recommendations from an expert group.J. Neurol. Neurosurg. Psychiatry2016872117125 26492930
     [Google Scholar]
  8. LiE. GohA. GuptaS. SchaufM. ChenA. HartungD.M. Budget impact analysis of biosimilar Natalizumab in the US.Am. J. Manag. Care2024307e191e19710.37765/ajmc.2024.89558 38995822
     [Google Scholar]
  9. KhoyK. MariotteD. DeferG. PetitG. ToutiraisO. Le MauffB. Natalizumab in multiple sclerosis treatment: From biological effects to immune monitoring.Front. Immunol.20201154984210.3389/fimmu.2020.549842 33072089
     [Google Scholar]
  10. Unilabs Stratify JCVAvailable from: https://test.unilabsweb.com/
  11. AdlerF.A.M. BartlT. WiegandR. KellerT. FreseM.A. MillhollandJ. MoulsonA. DerlaczR. A new assay for detection of anti-JCV antibodies to support risk stratification and monitoring for progressive multifocal leukoencephalopathy in patients considering or in treatment with natalizumab.Available from: https://www.charcot-ms.org/files/ID-99-Maja-Natek.pdf 2024
  12. HoP.R. KoendgenH. CampbellN. HaddockB. RichmanS. ChangI. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: A retrospective analysis of data from four clinical studies.Lancet Neurol.2017161192593310.1016/S1474‑4422(17)30282‑X 28969984
     [Google Scholar]
  13. PlavinaT. SubramanyamM. BloomgrenG. RichmanS. PaceA. LeeS. SchlainB. CampagnoloD. BelachewS. TichoB. Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab‐associated progressive multifocal leukoencephalopathy.Ann. Neurol.201476680281210.1002/ana.24286 25273271
     [Google Scholar]
  14. ImmunoWELL™ JCV IgG Test package insert.Available from: https://www.genbio.com/wp-content/uploads/documents/110-0182.pdf
  15. ThompsonA.J. BanwellB.L. BarkhofF. CarrollW.M. CoetzeeT. ComiG. CorrealeJ. FazekasF. FilippiM. FreedmanM.S. FujiharaK. GalettaS.L. HartungH.P. KapposL. LublinF.D. MarrieR.A. MillerA.E. MillerD.H. MontalbanX. MowryE.M. SorensenP.S. TintoréM. TraboulseeA.L. TrojanoM. UitdehaagB.M.J. VukusicS. WaubantE. WeinshenkerB.G. ReingoldS.C. CohenJ.A. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.Lancet Neurol.201817216217310.1016/S1474‑4422(17)30470‑2 29275977
     [Google Scholar]
  16. RyersonL.Z. FoleyJ. ChangI. KisterI. CutterG. MetzgerR.R. GoldbergJ.D. LiX. RiddleE. SmirnakisK. KasliwalR. RenZ. HotermansC. HoP.R. CampbellN. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.Neurology20199315e1452e146210.1212/WNL.0000000000008243 31515290
     [Google Scholar]
  17. TYRUKO (natalizumab) Treatment initiation form.Available from: https://www.medicines.org.uk/emc/rmm/2992/Document
  18. LandisJ.R. KochG.G. The measurement of observer agreement for categorical data.Biometrics197733115917410.2307/2529310 843571
     [Google Scholar]
  19. Attachment I Summary of product features.Available from: https://ec.europa.eu/health/documents/community-register/2023/20230922160180/anx_160180_it.pdf
  20. HalimiV. DaciA. Ancevska NetkovskaK. SuturkovaL. BabarZ.U.D. GrozdanovaA. Clinical and regulatory concerns of biosimilars: A review of literature.Int. J. Environ. Res. Public Health20201716580010.3390/ijerph17165800 32796549
     [Google Scholar]
  21. SchreitmüllerT. BartonB. ZharkovA. BakalosG. Comparative immunogenicity assessment of biosimilars.Future Oncol.201915331932910.2217/fon‑2018‑0553 30278780
     [Google Scholar]
  22. ZhuC. KalincikT. HorakovaD. ZhouZ. BuzzardK. SkibinaO. AlroughaniR. IzquierdoG. EichauS. KuhleJ. PattiF. Grand’MaisonF. HodgkinsonS. GrammondP. Lechner-ScottJ. ButlerE. PratA. GirardM. DuquetteP. MacdonellR.A.L. Weinstock-GuttmanB. OzakbasS. SleeM. SaM.J. Van PeschV. BarnettM. Van WijmeerschB. GerlachO. PrevostJ. TerziM. BozC. LaureysG. Van HijfteL. KermodeA.G. GarberJ. YamoutB. KhouryS.J. MerloD. MonifM. JokubaitisV. van der WaltA. ButzkuevenH. LeistT.P. HabibL. UdugamaP. GrayO. HorakovaD. SartoriC. MoreR. SiddiquiA. FarrP. StuparD. TangC. LeA. SmirnovaS. PalshetkarG. SpelmanT. Comparison between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation.JAMA Neurol.202380773974810.1001/jamaneurol.2023.1542 37273217
     [Google Scholar]
  23. FoongY.C. MerloD. GresleM. BuzzardK. ZhongM. YehW.Z. JokubaitisV. MonifM. SkibinaO. OzakbasS. PattiF. GrammondP. AmatoM.P. KalincikT. HorakovaD. Kubala HavrdovaE. Weinstock-GuttmanB. LechnerS.J. BozC. SaM.J. ButzkuevenH. van der WaltA. ZhuC. Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.J. Neurol. Neurosurg. Psychiatry202495876777410.1136/jnnp‑2023‑332883 38453478
     [Google Scholar]
/content/journals/cn/10.2174/011570159X372688250226110925
Loading
Comparing STRATIFY JCV™ DxSelect™ and IMMUNOWELL™ JCV Tests in RRMS to Assess PML Risk
Curr. Neuropharmacol. 23, 1294 (2025); https://doi.org/10.2174/011570159X372688250226110925
/content/journals/cn/10.2174/011570159X372688250226110925
/content/journals/cn/10.2174/011570159X372688250226110925
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): antibody test; immunosuppressant drugs; IMMUNOWELL™ JCV; JC virus; natalizumab; PML risk; STRATIFY JCV™ DxSelect™

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test